Integration of human pancreatic islet genomic data refines regulatory mechanisms at Type 2 Diabetes susceptibility loci

  1. Matthias Thurner
  2. Martijn van de Bunt
  3. Jason M Torres
  4. Anubha Mahajan
  5. Vibe Nylander
  6. Amanda J Bennett
  7. Kyle J Gaulton
  8. Amy Barrett
  9. Carla Burrows
  10. Christopher G Bell
  11. Robert Lowe
  12. Stephan Beck
  13. Vardhman K Rakyan
  14. Anna L Gloyn
  15. Mark I McCarthy  Is a corresponding author
  1. University of Oxford, United Kingdom
  2. University of California, San Diego, United States
  3. Kings College London, United Kingdom
  4. Barts and The London School of Medicine and Dentistry, United Kingdom
  5. University College London, United Kingdom

Abstract

Human genetic studies have emphasised the dominant contribution of pancreatic islet dysfunction to development of Type 2 Diabetes (T2D). However, limited annotation of the islet epigenome has constrained efforts to define the molecular mechanisms mediating the, largely regulatory, signals revealed by Genome-Wide Association Studies (GWAS). We characterised patterns of chromatin accessibility (ATAC-seq, n=17) and DNA methylation (whole-genome bisulphite sequencing, n=10) in human islets, generating high-resolution chromatin state maps through integration with established ChIP-seq marks. We found enrichment of GWAS signals for T2D and fasting glucose was concentrated in subsets of islet enhancers characterised by open chromatin and hypomethylation, with the former annotation predominant. At several loci (including CDC123, ADCY5, KLHDC5) the combination of fine-mapping genetic data and chromatin state enrichment maps, supplemented by allelic imbalance in chromatin accessibility pinpointed likely causal variants. The combination of increasingly-precise genetic and islet epigenomic information accelerates definition of causal mechanisms implicated in T2D pathogenesis.

Data availability

The following data sets were generated
    1. M Thurner et al
    (2017) Islet open chromatin data
    Available through controlled access at the EGA website (study accession no: EGAS00001002592).
    1. M Thurner et al
    (2017) Islet DNA methylation data
    Available through controlled access at the EGA website (study accession no: EGAS00001002592).
The following previously published data sets were used

Article and author information

Author details

  1. Matthias Thurner

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7329-9769
  2. Martijn van de Bunt

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6744-6125
  3. Jason M Torres

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  4. Anubha Mahajan

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  5. Vibe Nylander

    Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  6. Amanda J Bennett

    Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  7. Kyle J Gaulton

    Department of Pediatrics, University of California, San Diego, San Diego, United States
    Competing interests
    No competing interests declared.
  8. Amy Barrett

    Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  9. Carla Burrows

    Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  10. Christopher G Bell

    Department of Twin Research and Genetic Epidemiology, Kings College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  11. Robert Lowe

    Centre for Genomics and Child Health, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom
    Competing interests
    No competing interests declared.
  12. Stephan Beck

    Department of Cancer Biology, UCL Cancer Institute, University College London, London, United Kingdom
    Competing interests
    No competing interests declared.
  13. Vardhman K Rakyan

    Centre for Genomics and Child Health, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom
    Competing interests
    No competing interests declared.
  14. Anna L Gloyn

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1205-1844
  15. Mark I McCarthy

    The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
    For correspondence
    mark.mccarthy@drl.ox.ac.uk
    Competing interests
    Mark I McCarthy, Senior editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4393-0510

Funding

Wellcome (90367)

  • Matthias Thurner
  • Jason M Torres
  • Anna L Gloyn
  • Mark I McCarthy

Wellcome (90532)

  • Matthias Thurner
  • Jason M Torres
  • Anna L Gloyn
  • Mark I McCarthy

Wellcome (106130)

  • Matthias Thurner
  • Jason M Torres
  • Anna L Gloyn
  • Mark I McCarthy

Wellcome (98381)

  • Matthias Thurner
  • Jason M Torres
  • Anna L Gloyn
  • Mark I McCarthy

Wellcome (095101/Z/10/Z)

  • Matthias Thurner
  • Jason M Torres
  • Anna L Gloyn
  • Mark I McCarthy

Wellcome (200837/Z/16/Z)

  • Matthias Thurner
  • Jason M Torres
  • Anna L Gloyn
  • Mark I McCarthy

Wellcome (099673/Z/12/Z)

  • Matthias Thurner
  • Jason M Torres
  • Anna L Gloyn
  • Mark I McCarthy

Novo Nordisk

  • Martijn van de Bunt

Horizon 2020 Framework Programme (HEALTH-F4-2007-201413)

  • Vibe Nylander
  • Anna L Gloyn

Royal Society

  • Stephan Beck

National Institute for Health Research

  • Anna L Gloyn
  • Mark I McCarthy

National Institutes of Health (U01-DK105535)

  • Anna L Gloyn
  • Mark I McCarthy

National Institutes of Health (U01-DK085545)

  • Anna L Gloyn
  • Mark I McCarthy

National Institutes of Health (R01-DK098032)

  • Anna L Gloyn
  • Mark I McCarthy

National Institutes of Health (R01-MH090941)

  • Anna L Gloyn
  • Mark I McCarthy

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Marcelo Nobrega, University of Chicago, United States

Ethics

Human subjects: The Human Research Ethics Board at the University of Alberta (Pro00001754), the University of Oxford's Oxford Tropical Research Ethics Committee (OxTREC Reference: 2-15), or the Oxfordshire Regional Ethics Committee B (REC reference: 09/H0605/2) approved the studies. All organ donors provided informed consent for use of pancreatic tissue in research.

Version history

  1. Received: September 13, 2017
  2. Accepted: February 6, 2018
  3. Accepted Manuscript published: February 7, 2018 (version 1)
  4. Version of Record published: February 27, 2018 (version 2)

Copyright

© 2018, Thurner et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,435
    views
  • 651
    downloads
  • 104
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Matthias Thurner
  2. Martijn van de Bunt
  3. Jason M Torres
  4. Anubha Mahajan
  5. Vibe Nylander
  6. Amanda J Bennett
  7. Kyle J Gaulton
  8. Amy Barrett
  9. Carla Burrows
  10. Christopher G Bell
  11. Robert Lowe
  12. Stephan Beck
  13. Vardhman K Rakyan
  14. Anna L Gloyn
  15. Mark I McCarthy
(2018)
Integration of human pancreatic islet genomic data refines regulatory mechanisms at Type 2 Diabetes susceptibility loci
eLife 7:e31977.
https://doi.org/10.7554/eLife.31977

Share this article

https://doi.org/10.7554/eLife.31977

Further reading

    1. Chromosomes and Gene Expression
    2. Genetics and Genomics
    Lisa Baumgartner, Jonathan J Ipsaro ... Julius Brennecke
    Research Advance

    Members of the diverse heterochromatin protein 1 (HP1) family play crucial roles in heterochromatin formation and maintenance. Despite the similar affinities of their chromodomains for di- and tri-methylated histone H3 lysine 9 (H3K9me2/3), different HP1 proteins exhibit distinct chromatin-binding patterns, likely due to interactions with various specificity factors. Previously, we showed that the chromatin-binding pattern of the HP1 protein Rhino, a crucial factor of the Drosophila PIWI-interacting RNA (piRNA) pathway, is largely defined by a DNA sequence-specific C2H2 zinc finger protein named Kipferl (Baumgartner et al., 2022). Here, we elucidate the molecular basis of the interaction between Rhino and its guidance factor Kipferl. Through phylogenetic analyses, structure prediction, and in vivo genetics, we identify a single amino acid change within Rhino’s chromodomain, G31D, that does not affect H3K9me2/3 binding but disrupts the interaction between Rhino and Kipferl. Flies carrying the rhinoG31D mutation phenocopy kipferl mutant flies, with Rhino redistributing from piRNA clusters to satellite repeats, causing pronounced changes in the ovarian piRNA profile of rhinoG31D flies. Thus, Rhino’s chromodomain functions as a dual-specificity module, facilitating interactions with both a histone mark and a DNA-binding protein.

    1. Genetics and Genomics
    2. Neuroscience
    Yifei Weng, Shiyi Zhou ... Coleen T Murphy
    Research Article

    Cognitive decline is a significant health concern in our aging society. Here, we used the model organism C. elegans to investigate the impact of the IIS/FOXO pathway on age-related cognitive decline. The daf-2 Insulin/IGF-1 receptor mutant exhibits a significant extension of learning and memory span with age compared to wild-type worms, an effect that is dependent on the DAF-16 transcription factor. To identify possible mechanisms by which aging daf-2 mutants maintain learning and memory with age while wild-type worms lose neuronal function, we carried out neuron-specific transcriptomic analysis in aged animals. We observed downregulation of neuronal genes and upregulation of transcriptional regulation genes in aging wild-type neurons. By contrast, IIS/FOXO pathway mutants exhibit distinct neuronal transcriptomic alterations in response to cognitive aging, including upregulation of stress response genes and downregulation of specific insulin signaling genes. We tested the roles of significantly transcriptionally-changed genes in regulating cognitive functions, identifying novel regulators of learning and memory. In addition to other mechanistic insights, a comparison of the aged vs young daf-2 neuronal transcriptome revealed that a new set of potentially neuroprotective genes is upregulated; instead of simply mimicking a young state, daf-2 may enhance neuronal resilience to accumulation of harm and take a more active approach to combat aging. These findings suggest a potential mechanism for regulating cognitive function with age and offer insights into novel therapeutic targets for age-related cognitive decline.